Cargando…
Biological treatment usage in patients with HIV and rheumatic disease, 2003–2021: long-term safety and follow-up
OBJECTIVE: This study examined the safety and efficacy of biological agents, especially tumour necrosis factor (TNF) inhibitors, for HIV-positive rheumatology patients refractory to standard therapy. METHODS: This study is a retrospective case series including patients derived from a community HIV c...
Autores principales: | Naovarat, Benjamin Sornrung, Salazar, Gloria, Ishimori, Mariko, Williams, Francis M, Reveille, John D |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310260/ https://www.ncbi.nlm.nih.gov/pubmed/35863862 http://dx.doi.org/10.1136/rmdopen-2022-002282 |
Ejemplares similares
-
Biological agents for rheumatic diseases in the outbreak of COVID-19: friend or foe?
por: Santos, Cristiana Sieiro, et al.
Publicado: (2021) -
Exercise, infection and rheumatic diseases: what do we know?
por: Calabrese, Leonard, et al.
Publicado: (2021) -
SARS-CoV-2 vaccine safety in adolescents with inflammatory rheumatic and musculoskeletal diseases and adults with juvenile idiopathic arthritis: data from the EULAR COVAX physician-reported registry
por: Lawson-Tovey, Saskia, et al.
Publicado: (2022) -
Role of targeted therapies in rheumatic patients on COVID-19 outcomes: results from the COVIDSER study
por: Álvaro Gracia, Jose María, et al.
Publicado: (2021) -
Clinical outcomes of breakthrough COVID-19 after booster vaccination in patients with systemic rheumatic diseases
por: Fragoulis, George E, et al.
Publicado: (2022)